D.A. Davidson & Co’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

D.A. Davidson & Co’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-203	Closed	-$1K	–	2333
2017 Q2	$1K	Hold	203	–	–	﹤0.01%	2349
2017 Q1	$4K	Hold	203	–	–	﹤0.01%	2222
2016 Q4	$6K	Sell	203 -89	-30%	-$3.79K	﹤0.01%	2236
2016 Q3	$14K	Hold	292	–	–	﹤0.01%	1970
2016 Q2	$12K	Hold	292	–	–	﹤0.01%	1927
2016 Q1	$19K	Buy	292 +31	+12%	+$1.62K	﹤0.01%	1734
2015 Q4	$16K	Buy	261 +26	+11%	+$1.83K	﹤0.01%	1776
2015 Q3	$15K	Hold	235	–	–	﹤0.01%	1762
2015 Q2	$22K	Hold	235	–	–	﹤0.01%	1685
2015 Q1	$21K	Buy	235 +38	+19%	+$3.23K	﹤0.01%	1656
2014 Q4	$17K	Buy	197 +172	+688%	+$12.5K	﹤0.01%	1723
2014 Q3	$1K	Hold	25	–	–	﹤0.01%	2086
2014 Q2	$1K	Buy	+25	New	+$1.27K	﹤0.01%	2075

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.A. Davidson & Co's MACK Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 203 shares — an estimated $1K sold.

D.A. Davidson & Co first reported a position in MACK in Q2 2014 and held it in 13 quarters. The position peaked at $22K in Q2 2015. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

D.A. Davidson & Co reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
D.A. Davidson & Co sold 203 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $1K.
D.A. Davidson & Co first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2014 and held it in 13 quarters.
D.A. Davidson & Co's Merrimack Pharmaceuticals, Inc. position peaked at $22K in Q2 2015.
73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.